Universal Diagnostics — Series A (estimated) · €14M

Seville biotech Universal DX develops blood tests for early cancer detection. It closed a €14M round, €4M more than planned, funded by existing shareholders, to finish clinical work on its colon cancer test. It had raised €35M in total by then.

Lead not disclosed RoundSeries A (estimated) Announced14 Jan 2021 · as Universal DX CityMadrid · reported Sevilla SectorHealthtech & Bio · Biotech / Diagnostics Source W

Something wrong? Suggest a correction →